Larry Biegelsen
Larry Biegelsen
continue count expect increasing pursue
Don't count BSX out yet. We expect BSX to continue to pursue GDT by potentially modifying or increasing its $72/share offer.
board boston declare developed input latest likely offer scientific superior suspect
We suspect the new Boston Scientific offer was developed with input from the Guidant board, so it's likely that the Guidant board will declare it superior to J&J's latest offer.
believe boston credit maintain offer raise scientific share
We believe that Boston Scientific can raise its offer to $78 a share and still maintain an investment-grade credit rating.
although appears boston combining lingering scientific strategic
Although the strategic rationale for combining Boston Scientific and Guidant appears compelling, we have lingering concerns.
clear winner
In our view, Abbott is the clear winner in this deal.